Remove Chemotherapy Remove Compounding Remove FDA
article thumbnail

STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders

STAT

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. Testing of compounded drugs from these pharmacies revealed unknown impurities up to 33%, the company claims.

article thumbnail

US FDA approves Incyte’s merkel cell carcinoma therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Incyte ’s Zynyz (retifanlimab-dlwr) to treat metastatic or recurrent locally advanced merkel cell carcinoma (MCC) in adult patients. It is also being assessed in other tumour types and along with other Incyte pipeline compounds.

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pluvicto™ offers survival benefits for metastatic prostate cancer

European Pharmaceutical Review

The PSMAfore results are the second positive set of data for Pluvicto in a Phase III trial, after the VISION clinical trial, where PSMA–positive mCRPC patients who received Pluvicto plus standard of care (SoC) after ARPI and taxane-based chemotherapy, showed statistically significant reduction in risk of death. The PSMAfore study.

article thumbnail

Joint Basis for FDA/HHS Marijuana Rescheduling Recommendation Unveiled

The FDA Law Blog

Houck — In August 2023 the Food and Drug Administration (“FDA”) and Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. HHS forwards FDA’s analysis and recommendation to DEA. By Larry K.

FDA 69
article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

With alpha particles, you must be very careful how the drug is made to ensure that the compound remains stable between manufacturing and use. How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? What do you envision the future of radiopharmaceuticals to be like?

article thumbnail

2020 review – Pharma’s progress outside of COVID-19

pharmaphorum

The FDA has gone on to grant a fast review of the results ahead of a regulatory decision on the new lung cancer indication next year. While Trodelvy is already conditionally approved in the US, the data showing the drug improved overall survival compared with chemotherapy could be enough for it to clinch a permanent licence in the US.

FDA 96
article thumbnail

Panbela Therapeutics and Johns Hopkins to expand ivospemin development

Pharmaceutical Technology

Ivospemin is a subcutaneously administered polyamine analogue being developed by Panbela to induce polyamine metabolic inhibition (PMI) through the exploitation of an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumours.